Association of Electroencephalographic Alpha-2 Activity With Fluoxetine Response in Obsessive-Compulsive Disorder
*** Arıkan MK, Günver MG, İlhan R. Association of Electroencephalographic Alpha-2 Activity With Fluoxetine Response in Obsessive-Compulsive Disorder. J Clin Psychopharmacol. 2021 Jan 11. doi: 10.1097/JCP.0000000000001337.
Gamma oscillations predict paroxetine response of patients with Obsessive Compulsive Disorder
Background: Obsessive compulsive disorder is a distressing psychiatric illness with considerable treatment resistance rates. Prediction of treatment response leads to an increase in patient compliance and a decrease in morbidity. To decrease the treatment resistance rates, valid and useful instruments have been searched. Quantitative electroencephalography (QEEG) based markers have been objective predictors of the treatment response in psychiatric disorders.
Aim: This retrospective pilot study aims to explore QEEG as a biomarker to predict early response to paroxetine in OCD patients.
Method: Resting state QEEG and Yale-Brown Obsessive Compulsive Scale (Y-BOCS) were administered to 30 drug-free OCD patients without comorbidity. After maximum 12-week of treatment with paroxetine, patients with and without an early improvement were classified based on at least a 35% reduction in Y-BOCS scores. Pre-treatment QEEG data were compared between the two groups.
Results: Pre-treatment gamma, gamma 1 and gamma 2 oscillations were significantly higher in OCD patients who did not show an early improvement.
Conclusion: These preliminary results indicate that gamma oscillations could be acknowledged as the electrophysiological predictors of early clinical outcomes of OCD patients during paroxetine treatment.
Real-world efficacy of deep TMS for obsessive-compulsive disorder: Post-marketing data collected from twenty-two clinical sites
Background: Deep transcranial magnetic stimulation (dTMS) with the H7-coil was FDA cleared for obsessive-compulsive disorder (OCD) in August 2018 based on multicenter sham-controlled studies. Here we look at the efficacy of dTMS for OCD in real world practices.
Methods: All dTMS clinics were asked to supply their data on treatment details and outcome measures. The primary outcome measure was response, defined by at least a 30% reduction in the Yale Brown Obsessive Compulsive Scale (YBOCS) score from baseline to endpoint. Secondary outcome measures included first response, defined as the first time the YBOCS score has met response criteria, and at least one-month sustained response. Analyses included response rate at the endpoint (after 29 dTMS sessions), number of sessions and days required to reach first response and sustained response.
Results: Twenty-two clinical sites with H7-coils provided data on details of treatment and outcome (YBOCS) measures from a total of 219 patients. One-hundred-sixty-seven patients who had at least one post-baseline YBOCS measure were included in the main analyses. Overall first and sustained response rates were 72.6% and 52.4%, respectively. The response rate was 57.9% in patients who had YBOCS scores after 29 dTMS sessions. First response was achieved in average after 18.5 sessions (SD = 9.4) or 31.6 days (SD = 25.2). Onset of sustained one-month response was achieved in average after 20 sessions (SD = 9.8) or 32.1 days (SD = 20.5). Average YBOCS scores demonstrated continuous reduction with increasing numbers of dTMS sessions.
Conclusions: In real-world clinical practice, the majority of OCD patients benefitted from dTMS, and the onset of improvement usually occurs within 20 sessions. Extending the treatment course beyond 29 sessions results in continued reduction of OCD symptoms, raising the prospect of value for extended treatment protocols in non-responders.
Yiftach Roth, Aron Tendler, Mehmet Kemal Arikan, Ryan Vidrine, David Kent, Owen Muir, Carlene MacMillan, Leah Casuto, Geoffrey Grammer, William Sauve, Kellie Tolin, Steven Harvey, Misty Borst, Robert Rifkin, Manish Sheth, Brandon Cornejo, Raul Rodriguez, Saad Shakir, Taylor Porter, Deborah Kim, Brent Peterson, Julia Swofford, Brendan Roe, Rebecca Sinclair, Tal Harmelech, Abraham Zangen. Journal of Psychiatric Research. November 4, 2020.
Special Report on the Impact of the COVID-19 Pandemic on Clinical EEG and Research and Consensus Recommendations for the Safe Use of EEG
The global COVID-19 pandemic has affected the economy, daily life, and mental/physical health. The latter includes the use of electroencephalography (EEG) in clinical practice and research. We report a survey of the impact of COVID-19 on the use of clinical EEG in practice and research in several countries, and the recommendations of an international panel of experts for the safe application of EEG during and after this pandemic.
Methods: Fifteen clinicians from 8 different countries and 25 researchers from 13 different countries reported the impact of COVID-19 on their EEG activities, the procedures implemented in response to the COVID-19 pandemic, and precautions planned or already implemented during the reopening of EEG activities.
Results: Of the 15 clinical centers responding, 11 reported a total stoppage of all EEG activities, while 4 reduced the number of tests per day. In research settings, all 25 laboratories reported a complete stoppage of activity, with 7 laboratories reopening to some extent since initial closure. In both settings, recommended precautions for restarting or continuing EEG recording included strict hygienic rules, social distance, and assessment for infection symptoms among staff and patients/participants.
Conclusions: The COVID-19 pandemic interfered with the use of EEG recordings in clinical practice and even more in clinical research. We suggest updated best practices to allow safe EEG recordings in both research and clinical settings. The continued use of EEG is important in those with psychiatric diseases, particularly in times of social alarm such as the COVID-19 pandemic.